ALTERITY THERAPEUTICS LTD
Close on Oct 19, 2026
About Alterity Therapeutics
Pharmaceutical Preparations, SIC 2834
Alterity Therapeutics Limited is a clinical-stage biotechnology company focused on creating treatments for neurodegenerative conditions. The company utilizes a proprietary chemical library and platform technology aimed at redistributing excess labile iron and addressing protein aggregation in the central nervous system. Its lead oral drug candidate, ATH434, is designed to reduce alpha-synuclein pathology and preserve neurons, with primary clinical development focused on Multiple System Atrophy, alongside research in Parkinson’s disease and other disorders.
The company operates its chemistry program out of leased laboratory facilities at The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute in Australia, an establishment housing over 500 participants and scientists. Alterity maintains its registered and principal executive office in Melbourne, Victoria, Australia.
Summary of the business section of Alterity Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ALTERITY THERAPEUTICS LTD
- Founded
- 1997
- Headquarters
- Melbourne, Australia
- Address
- Level 15, 500 Collins Street VIC 3000
- Phone
- 61 3 9349 4906
- Website
- alteritytx.com
- Employees
- 11, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- C3
- Fiscal year ends
- June 30
- Auditor
- PricewaterhouseCoopers, Melbourne, Australia
Stock & identifiers
- Ticker
- ATHE
- Other tickers
- PRNAF
- Exchange
- Nasdaq
- IPO date
- Sep 29, 2003
- Shares outstanding
- 218M, Jun 30, 2026
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-50 reverse, Aug 28, 2026; 1-for-10 reverse, Jan 9, 2023; 1-for-6 reverse, Mar 24, 2016
- SEC CIK
- 1131343
- CUSIP
- 02155X205
- ISIN
- US02155X2053
- LEI
- 52990045JUZVZ9QL3159
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Allen Stamler | Chief Executive Officer, Director | 11,827,570 |
| Niven Abby Sarah Macnish | Chief Financial Officer | 454,545 |
| Peter Ashley Marks | Director | 191,340 |
| Lawrence Bernard Gozlan | Director | 4,545,455 |
| Julian Michael Babarczy | Director | – |
| Ann Michelle Cunningham | Director | – |
Employees
Headcount reported in annual reports
“As of June 30, 2026, we had 11 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 8, 2019 | Name change | Name changed from PRANA BIOTECHNOLOGY LTD to ALTERITY THERAPEUTICS LTD |
| Oct 31, 2014 | Late filing | Notification of late filing |
| Jan 2, 2003 | Late filing | Notification of late filing |